- Aimedbio’s
novel brain tumor therapeutics, P302, was selected as a government-initiated
drug development program by the Korean Drug Development Fund (KDDF).
- ‘P302’
is a first-in-class ADC therapeutics targeting a brain tumor specific fusion
oncogene.
- Aimedbio
has confirmed significant tumor killing effect of ‘P302’ candidate.
- Aimedbio
utilizes patients’ genetic/clinical data and patient-derived samples in the
antibody development process, resulting in higher probability of clinical success.
Link to full news: http://www.whosaeng.com/131514